Castrate-resistant Prostate Cancer Market Growth, Size, Trends Analysis - By Therapy - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Castrate-resistant Prostate Cancer Market Introduction and Overview

According to SPER market research, 'Global Castrate-resistant Prostate Cancer Market Size- By Therapy - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Castrate-resistant Prostate Cancer Market is predicted to reach 30.78 billion by 2034 with a CAGR of 8.91%.

This expansion is being driven by the rising prevalence of prostate cancer, particularly among the elderly, which is contributing to an increase in castrate-resistant prostate cancer (CRPC). Furthermore, advances in therapeutic alternatives, such as next-generation hormonal therapies, chemotherapy, and immunotherapies, are boosting market growth. The growing awareness of prostate cancer, as well as the need of early detection and treatment, are further driving market expansion.

Restraints: The limited effectiveness of treatments and their high costs are hindering market growth for CRPC. Many treatments are too expensive for patients without insurance, making them hard to access. The severe side effects from treatments like chemotherapy and immunotherapy can negatively affect patients' quality of life, making it hard to stick to their plans. Although there are various treatments for CRPC, not all patients will respond to them. Some may develop resistance, complicating disease management and prolonging survival challenges.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Therapy.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Sanofi, Johnson & Johnson Services, Inc, Pfizer, Inc, Astellas Pharma, Inc, Bayer AG.

Castrate-resistant Prostate Cancer Market Segmentation:

By Therapy: Based on the Therapy, Global Castrate-resistant Prostate Cancer Market is segmented as; Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA2541

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Castrate-resistant Prostate Cancer Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Castrate-resistant Prostate Cancer Market

7. Global Castrate-resistant Prostate Cancer Market, By Therapy (USD Million) 2021-2034

7.1. Chemotherapy
7.2. Hormonal Therapy
7.3. Immunotherapy
7.4. Radiotherapy

8. Global Castrate-resistant Prostate Cancer Market, (USD Million) 2021-2034

8.1. Global Castrate-resistant Prostate Cancer Market Size and Market Share

9. Global Castrate-resistant Prostate Cancer Market, By Region, (USD Million) 2021-2034

9.1. Asia-Pacific
- 9.1.1. Australia
- 9.1.2. China
- 9.1.3. India
- 9.1.4. Japan
- 9.1.5. South Korea
- 9.1.6. Rest of Asia-Pacific
9.2. Europe
- 9.2.1. France
- 9.2.2. Germany
- 9.2.3. Italy
- 9.2.4. Spain
- 9.2.5. United Kingdom
- 9.2.6. Rest of Europe
9.3. Middle East and Africa
- 9.3.1. Kingdom of Saudi Arabia
- 9.3.2. United Arab Emirates
- 9.3.3. Qatar
- 9.3.4. South Africa
- 9.3.5. Egypt
- 9.3.6. Morocco
- 9.3.7. Nigeria
- 9.3.8. Rest of Middle-East and Africa
9.4. North America
- 9.4.1. Canada
- 9.4.2. Mexico
- 9.4.3. United States
9.5. Latin America
- 9.5.1. Argentina
- 9.5.2. Brazil
- 9.5.3. Rest of Latin America

10. Company Profile

10.1. Sanofi
- 10.1.1. Company details
- 10.1.2. Financial outlook
- 10.1.3. Product summary
- 10.1.4. Recent developments
10.2. Johnson & Johnson Services, Inc
- 10.2.1. Company details
- 10.2.2. Financial outlook
- 10.2.3. Product summary
- 10.2.4. Recent developments
10.3. Pfizer, Inc
- 10.3.1. Company details
- 10.3.2. Financial outlook
- 10.3.3. Product summary
- 10.3.4. Recent developments
10.4. Astellas Pharma, Inc
- 10.4.1. Company details
- 10.4.2. Financial outlook
- 10.4.3. Product summary
- 10.4.4. Recent developments
10.5. Bayer AG
- 10.5.1. Company details
- 10.5.2. Financial outlook
- 10.5.3. Product summary
- 10.5.4. Recent developments
10.6. Others